Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology
Open Access
- 18 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 16 (12) , e1009107
Abstract
Mycolactone, a lipid-like toxin, is the major virulence factor of Mycobacterium ulcerans, the etiological agent of Buruli ulcer. Its involvement in lesion development has been widely described in early stages of the disease, through its cytotoxic and immunosuppressive activities, but less is known about later stages. Here, we revisit the role of mycolactone in disease outcome and provide the first demonstration of the pro-inflammatory potential of this toxin. We found that the mycolactone-containing mycobacterial extracellular vesicles produced by M. ulcerans induced the production of IL-1β, a potent pro-inflammatory cytokine, in a TLR2-dependent manner, targeting NLRP3/1 inflammasomes. We show our data to be relevant in a physiological context. The in vivo injection of these mycolactone-containing vesicles induced a strong local inflammatory response and tissue damage, which were prevented by corticosteroids. Finally, several soluble pro-inflammatory factors, including IL-1β, were detected in infected tissues from mice and Buruli ulcer patients. Our results revisit Buruli ulcer pathophysiology by providing new insight, thus paving the way for the development of new therapeutic strategies taking the pro-inflammatory potential of mycolactone into account.Keywords
Funding Information
- Inserm
- Fondation Raoul Follereau France
- Agence Nationale de la Recherche (grant no. ANR-15-IFEC-0006)
- MYCOPARADOX ANR project (grant no. ANR-16-CE12-0023)
- Conseil Régional des Pays de la Loire
- Fondation pour la Recherche Médicale (grant no. R20104NN)
- Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (grant no. ANR-10-LABX-62-IBEID)
- Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (grant no. ANR-10-LABX-62-IBEID)
- Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (grant no. ANR-10-LABX-62-IBEID)
- Agence Nationale de la Recherche (grant no. ANR-10-IAHU-01)
- Agence Nationale de la Recherche (grant no. ANR-10-IAHU-01)
- Agence Nationale de la Recherche (grant no. ANR-10-IAHU-01)
- Conseil Régional des Pays de la Loire
- Fondation Raoul Follereau France
This publication has 68 references indexed in Scilit:
- Effects of 15d‐PGJ2‐loaded poly(D,L‐lactide‐co‐glycolide) nanocapsules on inflammationBritish Journal of Pharmacology, 2010
- Buruli ulcerClinics in Dermatology, 2009
- IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiationProceedings of the National Academy of Sciences, 2009
- Chronic Mycobacterium marinum infection acts as a tumor promoter in Japanese Medaka (Oryzias latipes)Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 2009
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksBioinformatics, 2009
- Mycolactone Is Responsible for the Painlessness of Mycobacterium ulcerans Infection (Buruli Ulcer) in a Murine StudyInfection and Immunity, 2008
- Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer ( Mycobacterium ulcerans Disease)Antimicrobial Agents and Chemotherapy, 2007
- Systemic and local interferon-gamma production following Mycobacterium ulcerans infectionClinical and Experimental Immunology, 2007
- Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected withMycobacterium ulceransHas Implications for the Control of InfectionInfection and Immunity, 2007
- Pathogenesis ofHelicobacter pyloriInfectionClinical Microbiology Reviews, 2006